Here are four notes:
1. Mr. Distin has held a number of senior sales and business development positions at Parkus Medical, Osiris Therapeutics, Nuortho Surgical, RTI Biologics and CryoLife.
2. The company’s market strategy in the U.S. will focus on human tissue applications, initially starting with OrthoPure HT.
3. Tissue Regenix currently has ongoing clinical trials for the OrthoPure XM and OrthoPure XT products in Europe.
4. Mr. Distin will begin his new role on March 1.
More articles on devices:
LDR’s Mobi-C Cervical Disc associated with cost-effectiveness as compared to ACDF, 5-year outcomes study finds: 3 takeaways
Friedberg Investment Management reduces position in K2M by 8.2%: 4 key notes
Amedica shares soar by 2k+%: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
